Mirtazapina Viatris Pharmaceuticals (Mirtazapine)

Mirtazapine increases the release of norepinephrine and serotonin by blocking presynaptic α2‑adrenergic receptors, and it antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors. Its strong H1‑receptor antagonism adds sedative and appetite‑stimulating effects.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to therapeutic guidelines and patient needs.

Mirtazapine should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers assess each case individually and discuss possible alternatives.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with SSRIs, mirtazapine has a distinct mechanism that often results in faster improvement of sleep and appetite. It may be preferred when sedation or weight gain is beneficial, but it can cause more pronounced sedation than many SSRIs.

Mirtazapina Viatris should be stored at room temperature, preferably below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mirtazapine is taken orally, usually once daily in the evening due to its sedative effect. Tablets should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hypersensitivity reactions, suicidal thoughts especially early in treatment, and rare cardiac arrhythmias. Patients should be monitored closely for any signs of these conditions and seek immediate medical attention if they occur.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment without appropriate medical supervision.